Please login to the form below

Not currently logged in
Email:
Password:

Astellas Pharma

This page shows the latest Astellas Pharma news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Orchard Therapeutics raises 150m, Astellas swoops for early-stage gene company, Amicus gets FDA Fabry approval

Daily Brief: Orchard Therapeutics raises 150m, Astellas swoops for early-stage gene company, Amicus gets FDA Fabry approval

Daily Brief: Orchard Therapeutics raises 150m, Astellas swoops for early-stage gene company, Amicus gets FDA Fabry approval. ... Astellas acquires UK gene therapy company Quethera. Japan’s Astellas Pharma is to acquire UK-based gene therapy company

Latest news

More from news
Approximately 1 fully matching, plus 100 partially matching documents found.

Latest Intelligence

  • The good, the bad and the ugly The good, the bad and the ugly

    AstraZeneca, Takeda, Astellas Pharma, Novo Nordisk and Recordati take up the final five positions, though only two - Takeda (3.9%) and Astellas (9.3%) - recorded growth. ... The data this article was based on is available in full online:

  • Case study: Action on Fistula Case study: Action on Fistula

    Client:Astellas Pharma EMEA Limited. Agency:Forster Communications. Campaign:Action on Fistula. Timescale:. A quick look. ... Action on Fistula, launched in May 2014, is an innovative partnership between Astellas Pharma EMEA Limited and the charity

  • Case study: Action on Fistula Case study: Action on Fistula

    Client:Astellas Pharma EMEA Limited. Agency:Forster Communications. Campaign:Action on Fistula. Timescale:. A quick look. ... Action on Fistula, launched in May 2014, is an innovative partnership between Astellas Pharma EMEA Limited and the charity

  • Japanese pharma pulls no punches with post-Brexit UK Japanese pharma pulls no punches with post-Brexit UK

    Japanese pharma pulls no punches with post-Brexit UK. Firm want reassurance from the UK on its future in science and innovation. ... Yasuo Sakae, vice president of corporate strategy and planning at Astellas Pharma Europe, told PME that the company’s

  • Deal Watch July 2016 Deal Watch July 2016

    $225m. $36m. LEO Pharma. AstraZeneca. $1, 115m. $115m. Astellas. Cytokinetics. $100m. ... In at numbers 2, 3 and 4 are the LEO-AstraZeneca deal with an upfront of $115m, Astellas-Cytokinetics at $95m and Almirall-Sun Pharma at $50m (see below).

More from intelligence
Approximately 1 fully matching, plus 20 partially matching documents found.

Latest appointments

  • Astellas strengthens US and Canadian leadership team Astellas strengthens US and Canadian leadership team

    Astellas has promoted Steve Sabus (pictured right) to general manager of Astellas Pharma Canada, effective from 1 April this year. ... needs.”. Sabus joined Astellas in 2007 and has over 25 years’experience in the pharmaceutical industry.

  • Dendreon appoints new R&D lead Dendreon appoints new R&D lead

    Joining from Astellas Pharma, Dr Brown most recently served as senior medical director of oncology, where he led US medical strategy for the prostate cancer drug Xtandi (enzalutamide).

  • Stephen Eck joins Aravive Biologics Stephen Eck joins Aravive Biologics

    testing. Eck has served a number of global pharmaceutical companies in senior roles, including Eli Lilly and Pfizer, and most recently at Astellas Pharma as vice president of oncology medical sciences.

  • Astellas names Bob Chib to development leadership role Astellas names Bob Chib to development leadership role

    Astellas names Bob Chib to development leadership role. He takes up corporate strategy and planning position. ... Japanese pharma company Astellas has appointed Bob Chib to a leadership role within its US corporate development function.

  • MDxHealth creates new global commercial team MDxHealth creates new global commercial team

    He brings over 30 years of pharmaceutical sales expertise to the roles, having held senior positions at Astellas Pharma, Lederle, Roussel Laboratoria and Yamanouchi.

More from appointments
Approximately 0 fully matching, plus 14 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics